Progressive supranuclear palsy’s economical burden: the use and costs of healthcare resources in a large health provider in Israel

摘要

Abstract Background Progressive supranuclear palsy (PSP) is a rare and fatal neurodegenerative movement disorder with no disease modifying therapy currently available. Data on the costs associated with PSP are scarce. This study aims to assess the direct medical expenditure of patients with PSP (PwPSP) throughout disease course.Methods This retrospective cohort study is based on the data of a large state-mandated health provider in Israel. We identified PwPSP who were initially diagnosed between 2000 and 2017. Each PwPSP was randomly matched to three health-plan members without PSP by birth-year, sex, and socioeconomic status. Healthcare resources’ utilization and related costs were assessed.Results We identified 88 eligible PwPSP and 264 people in the reference group; mean age at diagnosis was 72.6?years (SD?=?8.4) and 53.4 were female. The annual direct costs of PwPSP have risen over time, reaching US$ 21,637 in the fifth year and US$ 36,693 in the tenth year of follow-up vs US$ 8910 in the year prior diagnosis. Compared to people without PSP, PwPSP had substantially higher medical expenditure during the years prior- and post-index date.Conclusion The present study demonstrates higher economic burden, which increases with time, in PwPSP as compared to those without.